Parkinson's disease. Parkinson's disease
Conditions
Interventions
Intervention 1: Intervention group 1 will receive cognitive stimulation based on enjoyable occupations combined with motivational feedback. The protocol consists of 12 sessions over 6 weeks (2 session
(2) embedding cognitive tasks (memory, attention, executive functions) within the activities
(3) providing verbal and visual motivational feedback during activities to enhance engagement and motivation. Intervention 2: The control group will receive routine occupational therapy interventions.
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: Being at the age of 65 years or older disease severity of 1–3 on the Hoehn & Yahr scale impairment of cognitive function, with a score of <24 on the Montreal Cognitive Assessment idiopathic Parkinson’s disease confirmed by a neurologist
Exclusion criteria
Exclusion criteria: Comorbid neurological/orthopedic conditions affecting mobility, per physician report Substance abuse History of diabetes mellitus
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Satisfaction of performance. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: The score of satisfaction with performance will be measured using the Canadian Occupational Performance Measure (COPM). This score reflects the participants' level of satisfaction with their performance in daily activities, rated on a 10-point scale, where higher scores indicate greater satisfaction.;Performance. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: The performance score will be measured using the Canadian Occupational Performance Measure (COPM). This score reflects the participants' level of performance in daily activities and is recorded on a 10-point scale, where higher scores indicate better performance. | — |
Secondary
| Measure | Time frame |
|---|---|
| Global cognitive function. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: Montreal Cognitive Assessment (MoCA), a screening tool assessing short-term memory, executive function, attention and concentration, language, and visuospatial skills. Total score ranges from 0 to 30, with higher scores indicating better cognitive performance.;Parkinson’s disease-specific cognitive function. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: Parkinson’s Disease Cognitive Rating Scale (PD-CRS), assessing cortical and subcortical cognition. Total score 0–134; lower scores reflect greater impairment.;Cognitive performance including attention, processing speed, and executive function. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: SCOPA-Cog (Scales for Outcomes in Parkinson’s Disease-Cognition), 10 items; total score 0–43, higher scores indicate better performance.;Cognitive control and selective attention. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: Stroop Test, naming ink color in incongruent conditions; outcomes: response time and error count.;Processing speed and cognitive flexibility. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: Trail Making Test (TMT), part A (numbers) and part B (alternating numbers and letters). Main outcome: completion time.;Executive function and visuospatial memory. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: Clock Drawing Test (CDT), drawing a clock with a set time; scored for accuracy and correct placement of hands.;Anxiety level. Timepoint: Baseline, post-intervention (week 12), and follow-up (week 18). Method of measurement: Hospital Anxiety and Depression Scale (HADS), anxiety subscale with 7 items (scored 0–3). Higher scores = greater anxiety. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Mehdizadeh
Iran University of Medical Sciences
Outcome results
None listed